Big Genes Are Back

One more genomewide linkage map, this for a fish called the three-spined stickleback, was announced late last year to not much fanfare.1 But rather than just another stride in the march of genomics, the accomplishment heralded a new way to approach a question that has stumped evolutionary biologists for decades: What is the architecture of genetic change? The model organisms for which linkage maps have been created are often bred in the laboratory to express certain phenotypes, and they can reve

Written bySteve Bunk
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

"The whole notion of the stickleback work was to get out of the mode or trap of betting on a candidate gene, and then doing a lot of work to see if you're right," notes the team's leader, Stanford University developmental biologist David M. Kingsley. Instead, he devised a top-down method that starts with the organism and the genome. This approach facilitates investigation into a central question of genetic architecture: do genes of large phenotypic effect exist, or does evolution proceed solely via micromutation, cumulative changes to multiple genes of small effect?

The question goes back to Charles Darwin, who favored continual accrual of small variations. But after him, early geneticists held that adaptation involves macromutations. Then, in the second half of the 20th century, the Modern Synthesis of Darwinism and genetics pushed the pendulum back to micromutations. However, a recent accumulation of both experimental and genetic evidence has returned ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies